- Levothyroxine is not associated with significantly improved QoL in patients aged 80+ years with subclinical hypothyroidism (SCH).
Why this matters
- The benefits of levothyroxine were unclear in this patient population.
- Thyroid-Related Quality of Life Patient-Reported Outcome (ThyPRO) hypothyroid symptoms scores showed a similar decrease in patients receiving levothyroxine and patients receiving placebo at 12 months (adjusted between-group difference, 1.27; P=.53).
- At study end, adjusted between-group difference was −0.48 (P=.88).
- ThyPRO tiredness scores showed a similar increase in patients receiving levothyroxine and patients receiving placebo at 12 months (adjusted between-group difference, −0.10; P=.96).
- At study end, adjusted between-group difference was −0.77 (P=.81).
- 29.5% of patients receiving levothyroxine and 28.8% of patients receiving placebo experienced a serious adverse event (estimated risk difference, −0.01; 95% CI, −0.04 to 0.01).
- 251 patients aged 80+ years with SCH pooled from 2 clinical trials were included.
- Funding: ZonMw; Swiss National Science Foundation; European Union; Swiss Heart Foundation; Velux Stiftung.
- Anti-thyroid antibody status not available.